SLE Flare
Lupus is the great mimicker. Flares can involve any organ. The most dangerous: lupus nephritis (Class III/IV/V), cerebral lupus, catastrophic APS, and diffuse alveolar hemorrhage. Labs: ↓ complement (C3/C4), ↑ anti-dsDNA = active disease.
🔍 Overview
Organ Involvement & Severity
| Organ | Manifestation | Severity |
|---|---|---|
| Skin / joints | Malar rash, discoid rash, photosensitivity, oral ulcers, arthralgia/arthritis (non-erosive) | Mild -treat with hydroxychloroquine ± NSAIDs |
| Serositis | Pleuritis, pericarditis | Moderate -steroids, NSAIDs, colchicine |
| Hematologic | Autoimmune hemolytic anemia (Coombs+), leukopenia, lymphopenia, thrombocytopenia | Moderate to severe -steroids, IVIG if severe thrombocytopenia |
| Renal (lupus nephritis) | Proteinuria, hematuria, rising Cr, nephrotic/nephritic syndrome. Class IV (diffuse proliferative) is most common and most severe. | Severe -renal biopsy, pulse steroids + mycophenolate or cyclophosphamide |
| CNS (cerebral lupus) | Seizures, psychosis, stroke, transverse myelitis, cognitive dysfunction | Severe -pulse steroids + cyclophosphamide. Rule out other causes (infection, TTP, APS). |
| Pulmonary | Diffuse alveolar hemorrhage (DAH), shrinking lung syndrome, ILD, pulmonary HTN | DAH = life-threatening -pulse steroids + cyclophosphamide + possible plasmapheresis |
Flare Markers
- ↓ C3 / C4 (complement consumed by immune complexes) -most sensitive marker of active disease
- ↑ Anti-dsDNA -correlates with lupus nephritis activity. Rising titers = impending flare.
- ↑ ESR with normal CRP -classic lupus pattern (CRP usually only rises in serositis or infection, not lupus flares). If CRP is high → think infection.
- Worsening cytopenias -active disease. But also consider medication side effects.
ESR ↑ + CRP normal = lupus flare. ESR ↑ + CRP ↑ = infection until proven otherwise. This distinction is clinically useful for differentiating flare vs infection in SLE patients (who are immunosuppressed and infection-prone).
💊 Management
Treatment by Severity
| Severity | Treatment |
|---|---|
| All patients (baseline) | Hydroxychloroquine (Plaquenil) 200–400 mg daily CORNERSTONE -reduces flares, organ damage, thrombosis, and mortality. Never stop. Annual eye exam for retinal toxicity. |
| Mild flare (skin, joints) | NSAIDs (short course) + topical steroids. Low-dose prednisone (≤ 7.5 mg/day). |
| Moderate flare (serositis, cytopenias) | Prednisone 0.5–1 mg/kg/day → taper. Add steroid-sparing: mycophenolate, azathioprine, or methotrexate. |
| Severe flare (nephritis Class III/IV, CNS, DAH) | Pulse methylprednisolone 1g IV daily × 3 days → prednisone 1 mg/kg. Then: mycophenolate (preferred for nephritis induction -ALMS, 2009) or cyclophosphamide (Euro-Lupus low-dose protocol for severe nephritis). Belimumab (anti-BAFF) for add-on in active lupus nephritis BLISS-LN, 2020. Voclosporin (calcineurin inhibitor) added to MMF for nephritis AURORA, 2021. |
📋 Clinical Example -Lupus Flare Assessment & Management
- Patient: 28F with known SLE, presents with fatigue, joint pain, malar rash, oral ulcers, Cr rising from 0.8 → 1.6 over 2 weeks.
- Flare workup:
- Labs: CBC (cytopenias?), BMP (renal), UA with microscopy (RBC casts = lupus nephritis), protein/creatinine ratio, complement C3/C4 (low = active disease), anti-dsDNA (rising titer = flare), ESR/CRP.
- UA: 2+ protein, 25 RBCs, RBC casts → active lupus nephritis. Protein/Cr ratio 2.8 (>0.5 = significant proteinuria).
- C3: 45 (low), C4: 8 (low), anti-dsDNA: 1:640 (elevated) → serologically active.
- Diagnosis: Class III/IV lupus nephritis until biopsy proves otherwise. Renal biopsy is MANDATORY -treatment depends on ISN/RPS class.
- Treatment:
- Mild flare (skin/joints only): Hydroxychloroquine (Plaquenil) 200mg BID (NEVER stop -reduces flares, thrombosis, and mortality). Low-dose prednisone (Deltasone) ≤10mg/day.
- Moderate flare (serositis, cytopenias): Prednisone 0.5-1mg/kg/day, taper over weeks.
- Severe flare (nephritis Class III/IV): Pulse methylprednisolone (Solu-Medrol) 500-1000mg IV × 3 days → prednisone 1mg/kg → taper. Induction: mycophenolate (CellCept) 2-3g/day OR cyclophosphamide (ALMS, 2009 -myco = cyclo for induction). Add belimumab (Benlysta) per BLISS-LN.
- Maintenance: Mycophenolate (CellCept) 1-2g/day + hydroxychloroquine indefinitely.
- Key: Hydroxychloroquine is the ONE drug every SLE patient should be on. Reduces flares, organ damage, and mortality.
📋 On Rounds
How do you distinguish lupus flare from infection in an immunosuppressed SLE patient?
This is one of the hardest clinical questions in rheumatology. Key clues: (1) CRP: low/normal in flare, elevated in infection. (2) Complement (C3/C4): drops in flare, normal or rises (acute phase) in infection. (3) Procalcitonin: elevated in bacterial infection, usually normal in flare (though not perfect). (4) Anti-dsDNA: rising in flare, stable in infection
Why is CRP typically normal in a lupus flare but elevated in infection?
In most autoimmune flares, CRP remains low or normal because lupus inflammation is driven by type I interferons, which actually suppress hepatic CRP production. In contrast, bacterial infection drives IL-6 release → potent CRP stimulation in the liver → CRP rises markedly. This makes CRP a useful discriminator: CRP < 5 + low C3/C4 + rising anti-dsDNA = flare. CRP > 50 + normal complements = infection.
Why should hydroxychloroquine never be stopped in SLE?
HCQ is the only SLE medication proven to reduce mortality -and the effect is dose-independent (even low doses help). Benefits: (1) Reduces flare frequency by 50-60%, (2) Reduces thrombosis risk (important in APS overlap), (3) Improves lipid profiles, (4) Reduces renal damage progression, (5) Safe in pregnancy (one of few SLE drugs that is). Stopping HCQ increases flare risk by 2.5× within 6 months. Even during remission, continue HCQ.
What are the indications for renal biopsy in lupus nephritis?
Biopsy is indicated whenever there is evidence of renal involvement in SLE -it determines the ISN/RPS class (I-VI) which directly guides treatment. Indications: (1) Proteinuria > 500 mg/day (UPCR > 0.5), (2) Active urine sediment (RBC casts, dysmorphic RBCs), (3) Unexplained rising creatinine, (4) Combination of proteinuria + hematuria even if individually below threshold. Why biopsy matters: Class I/II (minimal/mesangial)
Clinical Examples
📋 Case 1, Lupus Nephritis Class IV
Patient: 24-year-old woman with known SLE presenting with bilateral LE edema, foamy urine × 2 weeks, and fatigue. BP 148/92.
Key findings: UPCR 3.8 (nephrotic range), UA: 25 RBCs/hpf with RBC casts. C3 42 (low), C4 6 (low). Anti-dsDNA 1:640 (rising). CRP 1.8 (low). Renal biopsy: Class IV with crescents.
Management:
- Induction: mycophenolate 3g/day + prednisone 0.5-1 mg/kg ALMS, 2009
- Alternative: IV cyclophosphamide Euro-Lupus, 2004
- Continue HCQ (never stop). Consider belimumab BLISS-LN, 2020
- ACEi/ARB for proteinuria and BP
Teaching point: Cannot predict nephritis class clinically, biopsy is mandatory. Class IV is most common and aggressive. Low CRP + low complements = classic SLE flare pattern.
📋 Case 2, SLE Flare vs Infection
Patient: 32-year-old woman with SLE on mycophenolate and prednisone 10 mg, presenting with fever 39.1°C, fatigue, worsening joint pain × 3 days.
Key findings: CRP 42 (elevated). C3/C4 normal. Anti-dsDNA stable. Procalcitonin 2.4. Urine culture: E. coli.
Management:
- Infection, not flare, high CRP, normal complements, stable dsDNA, elevated procalcitonin
- Treat UTI per sensitivities. Hold mycophenolate during infection.
- Do NOT increase steroids. Resume MMF once cleared.
Teaching point: CRP low + C3/C4 low + dsDNA rising = flare. CRP high + C3/C4 normal + procalcitonin elevated = infection. When uncertain, cover both.
📋 Case 3, SLE in Pregnancy
Patient: 29-year-old woman with SLE (class III nephritis in remission × 18 months) on HCQ and azathioprine, now 8 weeks pregnant. Anti-Ro/SSA positive.
Key findings: Stable disease. UPCR 0.15. C3/C4 normal. aPL negative.
Management:
- Continue HCQ, safe, reduces neonatal lupus and flares
- Continue azathioprine, safe (unlike mycophenolate, which is teratogenic)
- Anti-Ro/SSA+ → fetal echo at 16 weeks for congenital heart block
- ASA 81 mg at 12 weeks (preeclampsia prophylaxis)
Teaching point: Safe: HCQ, azathioprine, low-dose prednisone. Teratogenic: mycophenolate, cyclophosphamide, MTX. Anti-Ro requires fetal cardiac monitoring.
📣 Sample Presentation
One-Liner
"Ms. Johnson is a 28-year-old with SLE presenting with facial rash, pleuritic chest pain, and UA showing 2+ protein and 15 RBCs/hpf. Anti-dsDNA elevated, C3/C4 low. CRP 2.4 (low). Consistent with lupus flare with possible nephritis."
Key Points to Cover on Rounds
SLE flare -active serology (rising anti-dsDNA, falling C3/C4). CRP low (supports flare over infection). Organ involvement: skin (malar rash), serositis (pleuritic chest pain -CXR: small left pleural effusion), renal (proteinuria + hematuria → nephritis?). Urine protein/Cr ratio sent -UPCR 2.4 (nephrotic range). Nephrology consulted for renal biopsy (needed for class determination → guides treatment). Hydroxychloroquine continued (never stop -reduces flares, thrombosis, mortality). Prednisone 0.5 mg/kg started pending biopsy. If class III/IV → mycophenolate or cyclophosphamide induction. Plan: renal biopsy this week, continue HCQ + steroids, check for infection before immunosuppression.
Monitoring Parameters
| Parameter | Frequency | Target / Action |
|---|---|---|
| Vitals | q4h floor, q1–2h ICU | HR, BP, RR, SpO₂, Temp -notify for significant deviations |
| Labs (BMP, CBC) | Daily AM or as indicated | Trend Cr, K⁺, WBC, Hgb -adjust treatment based on trajectory |
| Disease-specific markers | Per clinical context | See Overview and Management tabs for condition-specific targets |
| I&Os | Strict if volume-sensitive | UOP ≥ 0.5 mL/kg/hr. Net fluid balance guides diuresis or resuscitation. |
| Telemetry | Continuous if indicated | Arrhythmia detection. Discontinue when no longer indicated (reduces alarm fatigue). |
| Clinical response | Each assessment | Symptom improvement, functional status, appetite, mental status -the exam matters more than labs |
Don't just order labs -act on them. Every lab should have a clear clinical question. If you wouldn't change management based on the result, don't order it.
🧪 Workup
Workup -Systemic Lupus Erythematosus
ANA is the gate, not the diagnosis. It is highly sensitive and poorly specific, so it is useful to rule lupus out and nearly useless alone to rule it in. A negative ANA makes SLE very unlikely; a positive ANA in an otherwise well patient usually means nothing. Test only when there is a clinical reason.
| Test | What it tells you |
|---|---|
| ANA | Screening test. Positive in nearly all SLE, but also in healthy people, other autoimmune disease, and with age. Report the titre and pattern. |
| Anti-dsDNA | Specific for SLE and tracks disease activity, particularly lupus nephritis. Useful to follow serially once the diagnosis is made. |
| Anti-Smith | The most specific antibody for SLE, but present in only a minority. A positive result largely settles the diagnosis; a negative one excludes nothing. |
| C3 and C4 | Fall during active disease as complement is consumed. A falling complement with a rising dsDNA is the classic serologic signature of a flare, especially renal. |
| Urinalysis with sediment, plus urine protein:creatinine | The single most important test at every visit. Lupus nephritis is often silent until it is advanced, so proteinuria, hematuria and cellular casts are actively looked for rather than waited for. |
| CBC, creatinine, LFTs | Cytopenias are diagnostic criteria in their own right: hemolytic anemia, leukopenia, lymphopenia and thrombocytopenia. Creatinine tracks renal involvement. |
| Antiphospholipid antibodies | Lupus anticoagulant, anticardiolipin and anti-beta-2-glycoprotein I. Check at diagnosis, because they change thrombotic and pregnancy risk and therefore management. |
| Anti-Ro and anti-La | Relevant in pregnancy: they cross the placenta and cause neonatal lupus and congenital heart block, which changes fetal monitoring. |
| Renal biopsy | Indicated for significant proteinuria or an active sediment. The ISN/RPS class dictates whether the patient needs induction immunosuppression, so the biopsy drives treatment rather than confirming a hunch. |
Before starting hydroxychloroquine, arrange a baseline eye examination, then annual retinal screening from year five, or sooner with renal impairment or high dosing. Retinopathy is irreversible, and screening exists to catch it before vision is lost.
💊 Medications
Key Medications -Systemic Lupus Erythematosus
| Drug | Dose | Role | Watch for |
|---|---|---|---|
| Hydroxychloroquine EVERYONE | 5 mg/kg actual body weight per day, usually 200 to 400 mg | Background therapy for essentially every patient with SLE. Reduces flares, organ damage and mortality, and improves pregnancy outcomes. | Retinal toxicity is the dose-limiting harm, hence the weight-based cap and annual screening from year five. Do not stop it in pregnancy. |
| Glucocorticoids | Dose to severity; pulse methylprednisolone for organ-threatening disease | Fast control while a slower agent takes effect. | The goal is always to get off them. Cumulative steroid exposure, not lupus itself, causes much of the long-term damage. Taper deliberately and add a steroid-sparing agent early. |
| Mycophenolate mofetil | 2 to 3 g daily for induction | Lupus nephritis induction and maintenance, and useful in non-renal disease. | Teratogenic. Requires reliable contraception and a switch to azathioprine before a planned pregnancy. |
| Cyclophosphamide | Low-dose Euro-Lupus or NIH regimens | Severe organ-threatening disease: proliferative nephritis, CNS lupus, alveolar hemorrhage. | Gonadal toxicity, infection, hemorrhagic cystitis and later malignancy. Discuss fertility preservation before starting. |
| Belimumab | IV or subcutaneous | Active SLE and lupus nephritis, added to standard therapy. Anti-BLyS monoclonal. | Infection risk. Slow onset, so it is an add-on for persistent activity rather than a rescue drug. |
| Anifrolumab | IV every 4 weeks | Type I interferon receptor blocker for moderate to severe SLE, particularly skin and joint disease. | Not approved for lupus nephritis or CNS lupus, which is the distinction most often got wrong. Increased herpes zoster risk. |
| Voclosporin | Oral, with background therapy | Calcineurin inhibitor approved specifically for active lupus nephritis in combination with mycophenolate and steroids. | Monitor blood pressure and eGFR; calcineurin inhibitors are nephrotoxic, which is a particular consideration in a nephritis population. |
⚡ Summary
Summary
ANA Is the Gate, Not the Diagnosis
Highly sensitive and poorly specific, so it rules lupus out and is nearly useless alone to rule it in. A negative ANA makes SLE very unlikely; a positive ANA in an otherwise well patient usually means nothing. Anti-dsDNA and anti-Smith are the specific antibodies, and anti-dsDNA also tracks disease activity.
Track Flares With Complement and dsDNA
Falling C3 and C4 with rising anti-dsDNA indicates active disease, because complement is consumed by immune complexes. Trend them over time rather than reading a single set.
The ESR-CRP Split Separates Flare From Infection
Raised ESR with a normal CRP suggests a lupus flare. Raised ESR with a raised CRP is infection until proven otherwise. This distinction is genuinely useful in a population that is immunosuppressed, infection-prone, and in whom the two present almost identically. Serositis is the main lupus exception that does raise CRP.
Hydroxychloroquine for Everyone
It reduces flares, organ damage and mortality, and improves survival in lupus nephritis. Continue it through pregnancy and through flares. Annual retinal screening for the dose- and duration-related retinopathy, keeping the dose at or below 5 mg/kg of actual body weight.
Know the Dangerous Manifestations
Lupus nephritis (classes III, IV and V), cerebral lupus, catastrophic antiphospholipid syndrome and diffuse alveolar hemorrhage. These are the ones that kill, and they are treated with high-dose steroids plus an induction agent rather than with escalating outpatient therapy.
Biopsy the Kidney Rather Than Guessing
Proteinuria, an active sediment or a rising creatinine means a renal biopsy, because the class determines the treatment and cannot be predicted from the serology. Induction with mycophenolate or low-dose cyclophosphamide plus steroids, increasingly with belimumab or voclosporin added, then maintenance. Class IV carries the worst renal prognosis.
Minimize the Steroids Deliberately
Most long-term damage in lupus comes from corticosteroids rather than from the disease: osteoporosis, avascular necrosis, diabetes, cataracts, infection and cardiovascular disease. Use steroid-sparing agents early and taper with intent, rather than leaving patients on a maintenance dose indefinitely because it is easier.
Manage the Long-Term Risks
Accelerated atherosclerosis makes cardiovascular disease a leading cause of death, so treat conventional risk factors aggressively. Screen for antiphospholipid antibodies, which change anticoagulation and pregnancy management. Plan pregnancy during quiescent disease, and check anti-Ro and anti-La, which cause neonatal lupus and congenital heart block. Vaccinate before immunosuppression, and add PJP prophylaxis with high-dose steroids plus a cytotoxic agent.
Related Topics
Acute Gout & PseudogoutAntiphospholipid SyndromeDermatomyositis & PolymyositisPMR & Giant Cell ArteritisRheumatoid ArthritisScleroderma & Renal Crisis